TABLE 2 Adverse events (AEs) in the CHEST-2 study
Former riociguatFormer placeboTotal
Subjects n15582237
Any AE150 (97)78 (95)228 (96)
Individual AEs in >10% of patients
 Nasopharyngitis37 (24)18 (22)55 (23)
 Dizziness29 (19)16 (20)45 (19)
 Peripheral oedema24 (15)19 (23)43 (18)
 Diarrhoea21 (14)12 (15)33 (14)
 Cough20 (13)12 (15)32 (14)
 Dyspnoea18 (12)9 (11)27 (11)
 Upper respiratory tract infection18 (12)8 (10)26 (11)
Drug-related AE70 (45)39 (48)109 (46)
Discontinuation due to AE3 (2)5 (6)8 (3)
Serious AEs63 (41)37 (45)100 (42)
Discontinuation due to serious AE3 (2)4 (5)7 (3)
AEs of special interest in >5% of patients
 Syncope10 (6)7 (9)17 (7)
 Hypotension9 (6)6 (7)15 (6)
Other AEs of interest
 Haemoptysis/pulmonary haemorrhage5 (3)3 (4)8 (3)
  • Data are presented as n (%), unless otherwise stated. The mean treatment duration was 83 weeks.